

→ Please type a plus sign (+) inside this box →

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Unassigned
(Use as many sheets as necessary)				Filing Date	Herewith
Sheet	1	of	2	First Named Inventor	Shanker Lal GUPTA
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	224397

U.S. PATENT DOCUMENTS					
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication
		Application or Patent Number	Kind Code		
M.C.H	AA	4,499,082		Shenvi et al.	2/12/85
	AB	5,106,948		Kinder et al.	4/21/92
	AC	5,169,841		Kleeman et al.	12/8/92
	AD	5,187,157		Kettner et al.	2/16/93
	AE	5,242,904		Kettner et al.	9/7/93
	AF	5,250,720		Kettner et al.	10/5/93
	AG	5,492,900		LaHann	2/20/96
	AH	5,574,017		Gutheil	11/12/96
	AI	5,780,454		Adams et al.	7/14/98
	AJ	5,935,944		LaHann	8/10/99
	AK	5,990,083		Iqbal et al.	11/23/99
	AL	6,066,730		Adams et al.	5/23/00
	AM	6,083,903		Adams et al.	7/4/00
	AN	6,619,076		Shull et al.	1/2/01
	AO	6,297,217		Adams et al.	10/2/01
	AP	2002/0169114	A1	Gupta	11/14/02
M.C.H	AQ	2002/0188100	A1	Plamondon et al.	12/12/02

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Doc. No.	Foreign Patent Document			Date of Publication	Translation
		Office	Application or Patent Number	Kind Code		
M.C.H	AR	WO	98/35691	A1	Proscript, Inc.	8/20/98
	AS	WO	99/15183	A1	Proscript Inc.	4/1/99
	AT	WO	00/57887	A1	Glycosyn Pharmaceuticals, Inc.	10/5/00
	AU	WO	01/02424	A2	DuPont Pharmaceuticals Co.	1/11/01
	AV	WO	02/059130	A1	U.S. Government	1/8/02
M.C.H	AW	WO	02/059131	A1	Millennium Pharmaceuticals, Inc.	8/1/02

OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.			Translation
		Yes	No ⁺⁺		
M.C.H	AX	CIECHANOVER, "The Ubiquitin-Proteasome Proteolytic Pathway," <i>Cell</i> , Vol. 79, pp. 13-21 (October 7, 1994)			
M.C.H	AY	GENNARO, "Remington: The Science and Practice of Pharmacy," 20 th Edition, Chapter 42, pp. 802-803 (2000)			

Examiner Signature		Date Considered	5/25/05
--------------------	---	-----------------	---------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →

<p>Substitute for form 1449A/B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				Complete if Known			
Application Number		Unassigned		Filing Date		Herewith	
First Named Inventor		Shanker Lal GUPTA		Group Art Unit		Unassigned	
Examiner Name		Unassigned		Attorney Docket Number		224397	
Sheet	2	of	2				

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Signature 4/10 Date Considered 5/25/05

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).